

Clinical Policy: Crovalimab-akkz (PiaSky)

Reference Number: CP.PHAR.664

Effective Date: 06.20.24

Last Review Date: 08.26

Line of Business: Commercial, HIM/ICHRA, Medicaid

[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Crovalimab (PiaSky®) is a complement C5 inhibitor.

FDA Approved Indication(s)

PiaSky is indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and a body weight of at least 40 kg.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that PiaSky is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Paroxysmal Nocturnal Hemoglobinuria (must meet all):**

1. Diagnosis of PNH;
2. Prescribed by or in consultation with a hematologist;
3. Age $\geq$ 13 years;
4. Body weight $\geq$ 40 kg;
5. Flow cytometry shows detectable glycosylphosphatidylinositol (GPI)-deficient hematopoietic clones or $\geq$ 10% PNH cells;
6. Failure of a $\geq$ 3-month trial of Ultomiris® up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced; *^

**Prior authorization may be required for Ultomiris*

^For Illinois HIM requests, the step therapy requirements above do not apply as of 1/1/2026 per IL HB 5395

7. PiaSky is not prescribed concurrently with another FDA-approved product for PNH (e.g., Bkempv™, Epysqli™, Soliris®, Ultomiris, Empaveli®, Fabhalta®, Voydeya™);
8. Documentation of member's current body weight (in kg);
9. Dose does not exceed the following (a, b, c, and d):
 - a. IV loading dose on Day 1 (i or ii):
 - i. Weight $\geq$ 40 to < 100 kg: 1,000 mg;
 - ii. Weight $\geq$ 100 kg: 1,500 mg;
 - b. SC loading doses starting Day 2: 340 mg every week;
 - c. SC maintenance doses starting Day 29 (i or ii):
 - i. Weight $\geq$ 40 to < 100 kg: 680 mg every 4 weeks;
 - ii. Weight $\geq$ 100 kg: 1,020 mg every 4 weeks;

- d. If member is switching therapy from Soliris/Bkemv/Epysqli or Ultomiris, administration of the IV loading dose should occur at the time of the next scheduled C5 inhibitor dose.

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 6 months or to the member's renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Paroxysmal Nocturnal Hemoglobinuria (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy as evidenced by, including but not limited to, improvement in any of the following parameters (a – f):
 - a. Improved measures of intravascular hemolysis (e.g., normalization of lactate dehydrogenase [LDH]);
 - b. Reduced need for red blood cell transfusions;
 - c. Increased or stabilization of hemoglobin levels;
 - d. Less fatigue;
 - e. Improved health-related quality of life;
 - f. Fewer thrombotic events;
3. Documentation of member's current body weight (in kg);
4. PiaSky is not prescribed concurrently with another FDA-approved product for PNH (e.g., Bkemv, Epysqli, Soliris, Ultomiris, Empaveli, Fabhalta, Voydeya);

5. If request is for a dose increase, new dose does not exceed one of the following (a or b):
 - a. Weight $\geq$ 40 to $<$ 100 kg: 680 mg SC every 4 weeks;
 - b. Weight $\geq$ 100 kg: 1,020 mg SC every 4 weeks.

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 6 months or to the member's renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

GPI: glycosyl phosphatidylinositol

IV: intravenous

LDH: lactate dehydrogenase

PNH: paroxysmal nocturnal hemoglobinuria

SC: subcutaneous

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose																								
Ultomiris (ravulizumab- cwvz)	IV infusion: Day 1: Loading dose Day 15 and thereafter: Maintenance dose <table border="1"> <thead> <tr> <th>Body Weight Range (kg)</th><th>Loading Dose (mg)</th><th>Maintenance Dose (mg)</th></tr> </thead> <tbody> <tr> <td>≥ 5 to < 10</td><td>600</td><td>300 every 4 weeks</td></tr> <tr> <td>≥ 10 to < 20</td><td>600</td><td>600 every 4 weeks</td></tr> <tr> <td>≥ 20 to < 30</td><td>900</td><td>2,100 every 8 weeks</td></tr> <tr> <td>≥ 30 to < 40</td><td>1,200</td><td>2,700 every 8 weeks</td></tr> <tr> <td>≥ 40 to < 60</td><td>2,400</td><td>3,000 every 8 weeks</td></tr> <tr> <td>≥ 60 to < 100</td><td>2,700</td><td>3,300 every 8 weeks</td></tr> <tr> <td>≥ 100</td><td>3,000</td><td>3,600 every 8 weeks</td></tr> </tbody> </table>	Body Weight Range (kg)	Loading Dose (mg)	Maintenance Dose (mg)	≥ 5 to < 10	600	300 every 4 weeks	≥ 10 to < 20	600	600 every 4 weeks	≥ 20 to < 30	900	2,100 every 8 weeks	≥ 30 to < 40	1,200	2,700 every 8 weeks	≥ 40 to < 60	2,400	3,000 every 8 weeks	≥ 60 to < 100	2,700	3,300 every 8 weeks	≥ 100	3,000	3,600 every 8 weeks	3,600 mg/ 8 weeks
Body Weight Range (kg)	Loading Dose (mg)	Maintenance Dose (mg)																								
≥ 5 to < 10	600	300 every 4 weeks																								
≥ 10 to < 20	600	600 every 4 weeks																								
≥ 20 to < 30	900	2,100 every 8 weeks																								
≥ 30 to < 40	1,200	2,700 every 8 weeks																								
≥ 40 to < 60	2,400	3,000 every 8 weeks																								
≥ 60 to < 100	2,700	3,300 every 8 weeks																								
≥ 100	3,000	3,600 every 8 weeks																								

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): unresolved serious *Neisseria meningitidis* infection, hypersensitivity to crovalimab or any of the excipients
- Boxed warning(s): serious meningococcal infections

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
PNH	Body weight ≥ 40 kg to < 100 kg: Day 1: 1,000 mg IV Day 2, 8, 15, and 22: 340 mg SC Day 29 and every 4 weeks thereafter: 680 mg SC Body weight ≥ 100 kg: Day 1: 1,500 mg IV Day 2, 8, 15, and 22: 340 mg SC Day 29 and every 4 weeks thereafter: 1,020 mg SC	See regimen

VI. Product Availability

Single-dose vial: 340 mg/2 mL

VII. References

1. PiaSky Prescribing Information. South San Francisco, CA: Genentech, Inc.; June 2024. Available at: <https://www.piasky.com/> Accessed April 17, 2026.
2. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106(12):3699-3709. doi:10.1182/blood-2005-04-1717.

3. Borowitz MJ, Craig FE, DiGiuseppe JA, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry Part B (Clinical Cytometry). 2010; 78B: 211–23
4. ClinicalTrials.gov. NCT04432584. A study evaluating the safety, pharmacokinetics, and efficacy of crovalimab versus eculizumab in participants with paroxysmal nocturnal hemoglobinuria (PNH) currently treated with complement inhibitors (COMMODORE 1). Available at: <https://clinicaltrials.gov/study/NCT04432584>. Accessed May 1, 2025.
5. ClinicalTrials.gov. NCT04434092. A phase III study evaluating the efficacy and safety of crovalimab versus eculizumab in participants with paroxysmal nocturnal hemoglobinuria (PNH) not previously treated with complement inhibitors. (COMMODORE 2). Available at: <https://clinicaltrials.gov/study/NCT04434092>. Accessed April 27, 2026.
6. ClinicalTrials.gov. NCT04654468. A study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of crovalimab in participants with paroxysmal nocturnal hemoglobinuria (PNH) not previously treated with complement inhibition (COMMODORE 3). Available at: <https://clinicaltrials.gov/study/NCT04654468>. Accessed April 27, 2026.
7. Scheinberg P, Clé DV, Kim JS, et al. Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2024 Sep; 99(9): 1757-1767.
8. Röth A, He G, Tong H, et al. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition. Am J Hematol. 2024 Sep; 99(9): 1768-1777.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J1307	Injection, crovalimab-akkz, 10 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created pre-emptively	11.28.23	02.24
RT4: Drug is now FDA approved - criteria updated per FDA labeling: modified criteria to require age ≥ 13 years and body weight ≥ 40 kg, added documentation of member's current body weight, added criterion that members switching therapy from another C5 must administer dose at the time of next scheduled C5 inhibitor dose, clarified dose maximum to include only SC maintenance doses in the continued therapy section; references reviewed and updated.	06.26.24	
HCPCS code added [J1307] and removed codes [C9399, J3590].	11.07.24	
1Q 2025 annual review: no significant changes; for continued therapy added examples of improved extravascular hemolysis to	11.14.24	02.25

Reviews, Revisions, and Approvals	Date	P&T Approval Date
demonstrate positive response to therapy; references reviewed and updated.		
3Q 2025 annual review: removed example of improved extravascular hemolysis to demonstrate positive response to therapy given PiaSky's mechanism of action; revised continued approval duration from 6 to 12 months as PNH is a chronic condition; references reviewed and updated. Added step therapy bypass for IL HIM per IL HB 5395.	06.24.25	08.25
3Q 2026 annual review: per SDC, revised redirection from Soliris or Ultomiris to only Ultomiris; added ICHRA line of business; extended initial approval duration for Medicaid/HIM from 6 to 12 months and revised all approval durations for Commercial to "6 months or to the member's renewal date, whichever is longer" for this maintenance medication for a chronic condition; references reviewed and updated.	04.27.26	08.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan

retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2024 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.